Synergy Pharmaceuticals’ Chief Scientific Officer to Present Plenary Lecture at the 2014 Southern Regional Meetings

  Synergy Pharmaceuticals’ Chief Scientific Officer to Present Plenary Lecture
  at the 2014 Southern Regional Meetings

Business Wire

NEW YORK -- February 19, 2014

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced its Chief
Scientific Officer, Kunwar Shailubhai, Ph.D., M.B.A., will present a plenary
lecture entitled, “Cyclic GMP: Understanding its Evolution and Clinical
Implications in Gastroenterology,” during the Southern Gut Club meeting being
held at the InterContinental New Orleans on Thursday, February 20, at 7:00pm
(EST).

Cyclic GMP is a key intracellular mediator activated by the intestinal
guanylate cyclase-C (GC-C) receptor and is responsible for initiating
downstream GC-C signaling essential for maintenance of electrolytes and fluid
transport as well as in regulation of homeostasis in epithelial cells lining
the GI mucosa. The lecture will discuss the potential therapeutic applications
of GC-C agonists in a variety of GI diseases and disorders.

About Synergy

Synergy Pharmaceuticals Inc. is a biotechnology company focused on the
research and development of novel drugs for the treatment of gastrointestinal
(GI) diseases and disorders. Synergy has discovered proprietary analogs of the
human GI hormone, uroguanylin, the natural agonist for the intestinal
guanylate cyclase-C (GC-C) receptor. Both Synergy’s lead GC-C agonist,
plecanatide, and next-generation GC-C agonist, SP-333, mimic uroguanylin’s
natural functions by binding to and activating the GC-C receptor in the GI
tract to stimulate fluid and transit required for normal digestion.
Plecanatide is in phase 3 clinical trials for chronic idiopathic constipation
and a phase 2b study for irritable bowel syndrome with constipation. SP-333 is
in phase 2 development for opioid-induced constipation and is also being
explored for ulcerative colitis. For more information please visit
www.synergypharma.com.

Contact:

Media:
Synergy Pharmaceuticals Inc.
Gem Gokmen
Office: 212-584-7610
Mobile: 646-637-3208
ggokmen@synergypharma.com
or
Investors:
Bernard Denoyer
Office: 212-297-0020
Mobile: 203-300-8147
bdenoyer@synergypharma.com
 
Press spacebar to pause and continue. Press esc to stop.